BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
81.57
-1.62 (-1.95%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close83.19
Open83.71
Bid81.60 x 800
Ask81.56 x 1200
Day's Range81.41 - 83.64
52 Week Range79.13 - 106.74
Volume754,678
Avg. Volume1,335,961
Market Cap14.607B
Beta (3Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Health Care Digest: Why 2020 could be big for women's health, Trump's kidney order — and more
    American City Business Journals4 days ago

    Health Care Digest: Why 2020 could be big for women's health, Trump's kidney order — and more

    Myovant's plan to control heavy menstrual bleeding, how President Trump's executive order on kidney treatments could help a San Francisco company and more in our Health Care Digest.

  • Markit4 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BMRN had net inflows of $7.05 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Motley Fool8 days ago

    Shake-Up in Big Weed

    One of the marijuana industry’s pioneers was just ousted from Canopy Growth. What comes next?

  • BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shift From Loss To Profit
    Simply Wall St.10 days ago

    BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shift From Loss To Profit

    BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN): BioMarin Pharmaceutical Inc., a biotechnology company, develops and...

  • JP Morgan: 2 Gene Therapy Stocks to Buy Now
    TipRanks10 days ago

    JP Morgan: 2 Gene Therapy Stocks to Buy Now

    JP Morgan’s Cory Kasimov is making bullish bets on these two gene therapy stocks. This is an area with the potential to completely transform the healthcare landscape. It involves making changes to DNA to help treat, or potentially even cure, a disease. Although it is still early days, there are an estimated 10,000 diseases caused by a single mutation that can theoretically be corrected with a targeted gene therapy. These are known as monogenic diseases. “Though relatively rare, they affect millions of people worldwide” writes the World Health Organization, adding that in Canada monogenic diseases may account for up to 40% of the work of hospital based paediatric practice (Scriver, 1995).Here we take a closer look at two gene therapy stocks JP Morgan’s Kasimov believes is primed to outperform. Note that both these stocks also score a ‘Strong Buy’ consensus from top-performing analysts. That’s based on all the ratings received by each stock over the last three months. Let’s take a closer look now: BioMarin (BMRN)BioMarin is a world leader in developing innovative therapeutics for rare genetic diseases. “We believe BioMarin’s depth and breadth of orphan disease assets present a unique opportunity in biotech” cheers Kasimov. Indeed, the company has seven products on the market, and a growing product pipeline of multiple clinical and preclinical candidates. Excitingly, this includes valrox gene therapy for the treatment of Hemophilia A. This genetic disease is caused by the deficiency of clotting factor VIII. It is the most common type of hemophilia, with an estimated 90,000 patients in the territories where BioMarin operates.Currently the standard of care for severe hemophilia A patients is intravenous infusions three times a week. However many patients still experience spontaneous bleeding events- which can prove fatal. In contrast, gene therapy has the promise of delivering, in as little as a single administration, the missing gene needed to produce factor VIII. BioMarin has now revealed plans to submit valrox for regulatory approval in US/EU in 4Q19. Kasimov calls the news “an incremental positive that could serve to help firmly establish valrox in the commercial setting well ahead of any potential competitors.”He sees the stock as ‘undervalued’ at current levels and writes: “BMRN remains a high conviction long-term idea between its orphan-focused, diversified base business (>$1B in sales), growing commercial portfolio, and potentially disruptive late-stage pipeline.” Kasimov has a $133 price target on the stock (65% upside potential).In total, eleven top analysts have published buy ratings on the stock in the last three months. So no hold or sell ratings here. Meanwhile the $133 average analyst price target suggests sizable upside potential of 60% lies ahead. View BMRN Price Target & Analyst Ratings Detail Bluebird Bio (BLUE)Bluebird Bio is a clinical-stage company that, like BioMarin, is developing potentially transformative gene therapies for severe genetic and rare diseases. In particular, the company has just released updated results for LentiGlobin- a potential treatment and cure for sickle cell disease (SCD). Investors are keeping a close eye on the sickle cell opportunity, as this is a severe life-shortening blood disorder affecting around 110,000 patients in the US. Kasimov describes the latest results as ‘consistent’ and ‘incredibly profound’, adding that “the SCD data, in particular, reaffirms our prevailing view that… LentiGlobin is going to be exceedingly hard to beat by earlier-stage competition.” Bluebird expects filing and approval for LentiGlobin for SCD to take place in 2022.At the same time, it’s the company’s broad focus that really sets BLUE apart. “One particularly attractive yet underappreciated aspect of Bluebird is all the different technologies it has at its disposal”, says Kasimov. For BLUE that means using the right tools/ combinations to effectively design novel therapeutic- be it gene therapy, gene therapy, CAR T capabilities or even gene editing. For example, the company has also demonstrated encouraging initial data for bb2121, a CAR-T therapy for the potential treatment of multiple myeloma, that it is developing with Celgene (CELG). Net-net “We remain intrigued by an innovative company that has the potential to go 4-for-4 with its lead assets and has a multitude of tools in the shed (an anti-pure-play) to fuel the pipeline for a long time to come” says the analyst. He has a Street-high price target on BLUE of $195 (52% upside potential), and concludes: “In our opinion, BLUE is well positioned for long-term success.” Overall, top analysts agree with this upbeat outlook. Three out of four analysts rate the stock a ‘buy.’ We can also see that the $153 average analyst price target indicates upside potential of 19%.View BLUE Price Target & Analyst Ratings DetailView other top biotech stock ideas with the Top Analysts' Stocks tool

  • BioMarin (BMRN) to File for Hemophilia A Candidate in Q4
    Zacks11 days ago

    BioMarin (BMRN) to File for Hemophilia A Candidate in Q4

    BioMarin (BMRN) plans to file regulatory applications for gene therapy candidate for severe hemophilia A in the fourth quarter of 2019.

  • 3 Top Biotech Stocks to Buy in July
    Motley Fool11 days ago

    3 Top Biotech Stocks to Buy in July

    Here's why this team of biotech experts are giddy about these stocks right now.

  • Gene Therapy Battle: Why Sangamo Therapeutics Is Thrashing Its Rivals
    Investor's Business Daily12 days ago

    Gene Therapy Battle: Why Sangamo Therapeutics Is Thrashing Its Rivals

    Sangamo stock popped Monday after the biotech company unveiled promising results for its Pfizer-partnered gene therapy in hemophilia A treatment. Sangamo stock jumped as much as 16.9%.

  • Here's Why Sangamo Therapeutics Is Surging Today
    Motley Fool12 days ago

    Here's Why Sangamo Therapeutics Is Surging Today

    Results released late on Friday gave investors a reason to cheer.

  • Sarepta Stock Up Almost 40% This Year So Far: Here's Why
    Zacks12 days ago

    Sarepta Stock Up Almost 40% This Year So Far: Here's Why

    Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.

  • Facebook churns out a per-employee profit of $635K per year. How that compares with Apple, Google, Cisco, Oracle, Salesforce and others
    American City Business Journals12 days ago

    Facebook churns out a per-employee profit of $635K per year. How that compares with Apple, Google, Cisco, Oracle, Salesforce and others

    Facebook makes more profit per employee than any other tech company on the Fortune 500: A whopping $634,694 per year. Here's how that compares with other major tech employers like Google, Apple and Cisco.

  • Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?
    Market Realist17 days ago

    Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?

    Horizon Therapeutics (HZNP) is up 23.13%, and BioMarin (BMRN) is down 6.62% year-to-date. Let's study the drivers and risks for both these rare disease players in greater detail.

  • Morningstar19 days ago

    Healthcare: Drugmakers and Providers Look Attractive

    Morningstar's U.S. Healthcare Index has increased 1% quarter to date through June 21 and 9% year to date, trailing the market over both intervals (Exhibit 1) amid concern around healthcare pricing pressures.

  • 8 Stocks May Jump on Takeovers as Market Nears Peak
    Investopedia25 days ago

    8 Stocks May Jump on Takeovers as Market Nears Peak

    Both JPMorgan and Deloitte expect strong merger and acquisition activity ahead, and analysts believe that these stocks are likely targets.

  • Despite Recent Volatility, Biotech Stocks Look Poised to Pop
    Investopedia25 days ago

    Despite Recent Volatility, Biotech Stocks Look Poised to Pop

    Recent news from a leading gene therapy company highlights the risks, but the charts suggest ample room to the upside for biotech stocks.

  • BioMarin Gets $15M From Pfizer on Talzenna's European Nod
    Zacks26 days ago

    BioMarin Gets $15M From Pfizer on Talzenna's European Nod

    BioMarin (BMRN) gains a $15-million milestone from Pfizer on the approval of its breast cancer drug in Europe.

  • Pfizer's Talzenna Gets Approval in Europe for Breast Cancer
    Zacks26 days ago

    Pfizer's Talzenna Gets Approval in Europe for Breast Cancer

    Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.

  • Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up
    Investor's Business Dailylast month

    Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up

    Bitcoin trading was active again Monday amid a solid gain for the Nasdaq. The tech-laden index was helped by strength in software and biotech stocks.

  • Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license
    American City Business Journalslast month

    Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license

    Errant Gene Therapeutics claims in a new lawsuit that local venture capital firm Third Rock Ventures and bluebird bio CEO Nick Leschly worked to hinder its drug development efforts so it could obtain a key part of its intellectual property.

  • 9 major Bay Area tech employers pay a typical worker more than $200K per year
    American City Business Journalslast month

    9 major Bay Area tech employers pay a typical worker more than $200K per year

    Large Bay Area tech employers that pay a typical employee more than $200,000 per year include the typical suspects like Google parent Alphabet Inc., Facebook and Netflix. But several companies that are lesser-known outside Silicon Valley also pay top dollar for talent.

  • 'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases
    American City Business Journalslast month

    'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases

    Emil Kakkis launched Ultragenyx Pharmaceutical in Novato and the EveryLife Foundation for Rare Diseases, lobbying for legislative changes to make it easier to develop rare disease drugs.

  • Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. (BMRN)
    Insider Monkeylast month

    Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. (BMRN)

    Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

  • Should BioMarin Pharmaceutical (NASDAQ:BMRN) Be Disappointed With Their 32% Profit?
    Simply Wall St.last month

    Should BioMarin Pharmaceutical (NASDAQ:BMRN) Be Disappointed With Their 32% Profit?

    It hasn't been the best quarter for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shareholders, since the share price has...